RADDEL

Nanocapsules for targeted delivery of radioactivity

 Partecipanti

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The consortium RADDEL (RADioactivity DELivery) has a research-based approach for the training of the new generation of scientists in the development of novel functional nanomaterials . A well structured training program will be provided with a balanced combination of local and network-wide training through secondments, joint network meetings, workshops, schools, industrial training and the final network conference. The research program focuses on the design, synthesis, characterisation, pharmacological studies and dosimetry calculations of nanocapsules that seal in their interior radioactive materials for biomedical applications in the areas of cancer diagnosis and therapy. After sealing the chosen radionuclides, the external walls of the nanocapsules will be decorated with biomolecules to render them biocompatible and for targeting purposes. In a recent study we have recently observed that these nanocapsules allow the delivery of unprecedented radiodosage and remain stable for extended periods thus guaranteeing essentially zero leakage of the radionuclides. Surface functionalisation of these nanocapsules offers versatility towards modulation of tissue biodistribution of the radioemitting crystals in a manner determined by the nanocapsule that delivers them. The delivery of radioactivity takes place through the walls of nanocapsules (carbon) and release of the encapsulated radionuclides is therefore not needed and certainly not desired. The present research objectives go beyond the-state-of-the art in the field and innovative products and solutions are expected.'

Descrizione progetto (Article)

The very small sizes of nanomaterials enable them to travel within the body and even enter cells. Their virtually limitless capacity for surface functionalisation makes it possible to attach entities that modify their properties and/or functions. For example, modifications can impart biocompatibility, help them find their targets and be 'recognised' by them, and even enable them to be activated in some way for drug release or bioimaging.

With EU funding, the http://www.icmab.es/raddel/ (RADDEL) (Nanocapsules for targeted delivery of radioactivity) training network is preparing a new generation of scientists in nanomaterial-based cancer theranostics. The system under development is based on short CNTs that are filled with radionuclides and functionalised for biocompatibility and targeting.

Excellent progress has been achieved on the scientific side. Purification of CNTs and strategies for shortening them are under development and the team has now optimised the filling protocol. The radionuclides have been selected and scientists have successfully encapsulated non-radioactive (control or model) versions of them. A computer simulation will aid researchers in prediction of dosimetry, the radiation dose that is received by the cells and tissues.

Numerous different surface functionalisations are being explored and tested. Sugars (carbohydrates) and antibodies are among the most important natural cell recognition entities in general. The team is currently preparing carbohydrate-based ligands for targeting. Antibodies will be explored in the coming months. Preliminary studies on cellular uptake of some prepared nanocapsules are providing important insight.

So far, progress has contributed to seven publications in peer-reviewed scientific journals and many more in various stages of preparation and review. Fellows are spreading the word regarding their individual research projects via a strong presence at national and international conferences and workshops. The project has also established a Facebook profile and is preparing an annual newsletter and project brochure to share outcomes with a broad audience.

RADDEL's innovative approach to cancer diagnosis and radiotherapy is expected to have major impact on targeted theranostics for a devastating family of diseases. The technology could also open the door to similar systems for numerous other diseases. Participation of an industrial partner ensures strict adherence to market regulations and requirements, speeding commercialisation.